The Brain Institute of America, LLC was formed in March of 2017 with the goal of developing therapeutics for those with chronic neurological disorders including Alzheimer’s and Parkinson’s disease, as well as those with malignancies of the brain. The Institute was initiated after I experienced the loss of my father from glioblastoma multiform, and observing other colleagues witness the same.
The founder and president / CEO of the Institute Brian D. Adams, PhD, received his B.S. in Biology from King's College, his Ph.D in Biomedical Sciences from UCONN Health, and performed his postdoctoral work at Yale University and Beth Israel Deaconess Medical Center (Harvard Medical School).
The Institute has over a decade of experience in the noncoding RNA field, and we are using this knowledge to develop biomarkers for neurologic disorders and rare forms of brain cancer.
Since the formation of the Institute we have made collaborations across the country to foster the development of novel RNA biomarkers to detect these disorders. In order to develop cures for neurological disorders the mission of the Institute is to bring together academic scholars, oncologists, and private corporations to generate novel questions and to strategize on how to develop the tools necessary for detecting the early onset of these disorders, as well as to develop potent therapeutics to cure these diseases.
Maintaining these academic collaborations is essential in ensuring the success of the Institute. I am also very grateful to those who help in supporting our cause. Our team has decades of experience and we are dedicated to developing cures for those with neurological disorders and malignancies.